Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in EOCN — Galmed Pharmaceuticals Ltd.

CIK 1423053 MIAMI, FL
Back to EOCN Full portfolio

Position in EOCN

as of Jun 30, 2026 · filed Sep 2, 2026
Position Value
$0
+$0 QoQ
Shares Held
86,851
+663.1% QoQ
Ownership
8.13%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2021
13 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in EOCN Over Time

Shares Held

Position Value (USD)

Derivatives in EOCN

reported options exposure · as of Sep 30, 2023
CallValue
$0
CallShares
42
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $6,151,051,707 across 436 Biotechnology names. EOCN ranks #434 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ONC
BeOne Medicines Ltd.
 1,425,517 $406,229,578
2 BBIO
BridgeBio Pharma, Inc.
 3,760,028 $280,046,885
3 INSM
INSMED Inc
 2,556,973 $272,624,460
4 MDGL
Madrigal Pharmaceuticals, Inc.
 507,233 $272,358,759
5 VRTX
Vertex Pharmaceuticals Inc / Ma
 510,430 $253,545,893
6 JAZZ
Jazz Pharmaceuticals plc
 1,006,676 $242,578,715
7 MANE
Veradermics, Inc
 1,877,775 $230,853,658
8 ROIV
Roivant Sciences Ltd.
 5,576,261 $197,343,876

All Filings in EOCN

Export CSV
15 filing rows on record
Report Date Value (USD) Shares
2026-06-30 — 86,851
2026-03-31 — 11,382
2025-12-31 — 38,177
2025-09-30 — 50,492
2023-12-31 — 11,251
2023-09-30 — 42
2023-09-30 — 40,458
2023-03-31 — 40,844
2022-09-30 — 18,628
2022-06-30 — 59,625
2022-03-31 — 12,588
2021-09-30 — 28,114
2021-06-30 — 39,337
2021-06-30 — 13,600
2021-03-31 — 14,800